z-logo
open-access-imgOpen Access
Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin
Author(s) -
Danica L. Rowe,
Tuba Ozbay,
Ruth O’Regan,
Rita Nahta
Publication year - 2009
Publication title -
breast cancer basic and clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.741
H-Index - 23
ISSN - 1178-2234
DOI - 10.4137/bcbcr.s3067
Subject(s) - curcumin , breast cancer , triple negative breast cancer , cancer research , cancer , apoptosis , estrogen receptor , context (archaeology) , medicine , metastatic breast cancer , cancer cell , cytotoxic t cell , oncology , pharmacology , biology , in vitro , biochemistry , paleontology
In the current study, we sought to examine the effects of curcumin in a specific type of breast cancer called triple negative breast cancer. These cancers lack expression of the estrogen and progesterone receptors and do not over-express HER2. Current treatment for triple negative breast cancers is limited to cytotoxic chemotherapy, and upon relapse, there are not any therapies currently available. We demonstrate here that the bioactive food compound curcumin induces DNA damage in triple negative breast cancer cells in association with phosphorylation, increased expression, and cytoplasmic retention of the BRCA1 protein. In addition, curcumin promotes apoptosis and prevents anchorage-independent growth and migration of triple negative breast cancer cells. Apoptosis and BRCA1 modulation were not observed in non-transformed mammary epithelial cells, suggesting curcumin may have limited non-specific toxicity. This study suggests that curcumin and potentially curcumin analogues should be tested further in the context of triple negative breast cancer. These results are novel, having never been previously reported, and suggest that curcumin could provide a novel, non-toxic therapy, which could lead to improved survival for patients with triple negative breast cancer. Curcumin should be studied further in this subset of breast cancer patients, for whom treatment options are severely limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom